Biweekly docetaxel as second-line chemotheraphy of patients with advanced non-small cell lung cancer: A phase II study of the Galician Lung Cancer Group (GGCP 006-00)

Anti-Cancer Drugs

Volumn 15, Issue 5, 2004, Pages 489-494

  Vázquez, Sergio ^a,g   Grande, Carlos ^b   Amenedo, Margarita ^c   Fírvida, José Luis ^d   Lázaro, Martín ^e   Alonso, Guillermo ^c   Curiel, Teresa ^f   Huidobro, Gerardo ^b   Mel, José Ramón ^a   Ramos, Manuel ^c  

^a University Hospital Xeral Calde   (Spain)

^b H Meixoeiro   (Spain)

^c C Oncológico de Galicia ^*  (Spain)

^d Instituto de Investigación Biomédica Ourense Vigo Pontevedra   (Spain)

^e Department of Pneumology   (Spain)

^f Instituto de Salud Carlos III   (Spain)

^g Medical Oncology Service   (Spain)

Author keywords

Biweekly; Docetaxel; Non small cell lung cancer; Second line

Indexed keywords

DOCETAXEL;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DEATH; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEMATOLOGIC DISEASE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BONE NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG ADMINISTRATION SCHEDULE; ENDPOINT DETERMINATION; HUMANS; INFUSIONS, INTRAVENOUS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MIDDLE AGED; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 2942612357     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000127333.06439.0e     Document Type: Article

References (24)

1. Schiller JH. Current standards of care in small-cell and non-small-cell lung cancer. Oncology 2001; 61(suppl 1):3-13.
2. Georgoulias VA. Second-line chemotherapy in relapsing or refractory patients with non-small cell lung cancer. Lung Cancer 2002; 38:61-66.
3. Lara Jr PN, Lau DH, Gandara DR. Non-small-cell lung cancer progression after first-line chemotherapy. Curr Treat Options Oncol 2002; 3:53-58.
4. Fossella FV, Lee JS, Berille J, Hong WK. Summary of phase II data of docetaxel (Taxotere), an active agent in the first- and second-line treatment of advanced non-small cell lung cancer. Semin Oncol 1995; 22:22-29.
5. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18:2095-2103.
6. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000; 18:2354-2362.
7. Manegold C. Chemotherapy for advanced non-small cell lung cancer: standards. Lung Cancer 2001 ; 34(suppl 2):S165-S170.
8. Lilenbaum RC, Schwartz MA, Seigel L, Belette F, Blaustein A, Wittlin FN, et al. Phase II trial of weekly docetaxel in second-line therapy for nonsmall cell lung carcinoma. Cancer 2001; 92:2158-2163.
9. Serke M, Argiropulos D, Schönfeld N, Loddenkemper R. Second-line therapy with weekly docetaxel in resistant or relapsed non-small cell lung cancer (NSCLC): final results. Proc Am Soc Clin Oncol 2001; abstr 2841.
10. Garcia-López JL, Domine M, Garrido P, Leon A, Crespo C, Lastra E, et al. Early phase II of docetaxel in second-line of advanced non small cell lung cancer (NSCLC): preliminary results. Proc Am Soc Clin Oncol 2000; abstr 2113.
11. Schütte W, Nagel S, Lautenschläger C, Wollschläger B, Serke M. Randomized phase III study of weekly versus three-weekly docetaxel as second-line chemotherapy for advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002; abstr 1228.
12. Gridelli C, Illiano A, Salvagni S, Piantedosi F, Palazzolo G, Caffo O, et al. Effect on quality-of-life (QoL) of weekly vs 3-weekly docetaxel (D) in second-line treatment of advanced non-small-lung cancer. The DISTAL randomized phase 3 study. Proc Am Soc Clin Oncol 2003; 22:625 (abstr 2515).
13. Camps C, Massuti B, Jimenez AM, Maestu I, Almenar D, Garcia R, et al. Second-line docetaxel administrated every 3 weeks versus weekly in advanced non-small-cell lung cancer (NSCLC): a Spanish Lung Cancer Group (SLCG) phase III trial. Proc Am Soc Clin Oncol 2003; 22:625 (abstr 2514).
14. Petrioli R, Pozzessere D, Messinese S, Sabatino M, Ceciarini F, Marsili S, et al. Weekly low-dose docetaxel in advanced non-small cell lung cancer previously treated with two chemotherapy regimens. Lung Cancer 2003; 39:85-89.
15. Galetta D, Gebbia V, Giotta F, Durini E, Romito S, Borsellino N, et al. Gemcitabine and docetaxel every 2 weeks in advanced non-small cell lung cancer: a phase II study of the Gruppo Oncologico Italia Meridionale. Lung Cancer 2002; 38:79-84.
16. Frasci G, Comella P, Thomas R, Di Bonito M, Lapenta L, Capasso I, et al. Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study. Cancer Chemother Pharmacol 2004; 53:25-32.
17. Rigas J, Rothenberg ML, Davis TH, Maurer LH, Perez R, Meyer L, et al. Phase I clinical and pharmacokinetic study of docetaxel in combination with two gemcitabine infusion schedules. Proc Am Soc Clin Oncol 1999; 18:226a (abstr 870).
18. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47:207-214.
19. NCI. Guidelines for the Reporting of Adverse Drug Reactions. Bethesda, MD: Division of Cancer Treatment, National Cancer Institute; 1988.
20. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982; 38:143-151.
21. Kaplan ZL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Ass 1958; 53:457-481.
22. Khuri FR. Docetaxel for locally advanced or metastatic non-small-cell lung cancer. Current data and future directions as front-line therapy. Oncology (Huntingt) 2002; 16:53-62.
23. Georgoulias V. Docetaxel (taxotere) in the treatment of non-small cell lung cancer. Curr Med Chem 2002; 9:869-877.
24. 2) docetaxel in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 2001; 48:356-360.